NanoBio Secures Novel Antigen Source For Intranasal RSV Vaccine
Ann Arbor-based NanoBio Corp. last week announced a licensing agreement with the National Institutes of Health that represents a significant step forward in developing the first vaccine to protect against respiratory syncytial virus (RSV) infections.
